Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Sokolova

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancerMartin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
Cancer|January 30, 2026
Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot studyBruce Montgomery, Julie A Lynch, Jessica Brown, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
The Prostate|April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancerElisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 2, 2026
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate CancerTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
JCO Precision Oncology|September 19, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS RegistryStacy Loeb, Scott W Keith, Laura Gross, et al.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2026
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4Andrew J Armstrong, Michael J Morris, Wassim Abida, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancerMartin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
Cancer|January 30, 2026
Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot studyBruce Montgomery, Julie A Lynch, Jessica Brown, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
The Prostate|April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancerElisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 2, 2026
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate CancerTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
JCO Precision Oncology|September 19, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS RegistryStacy Loeb, Scott W Keith, Laura Gross, et al.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2026
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4Andrew J Armstrong, Michael J Morris, Wassim Abida, et al.
Pageof 6